Additionally, AMG-595 and depatuxizumab mafodotin (Depatux-m), both targeting EGFR VIII overexpressing glioblastoma multiform (GBM), were developed and improved therapeutic efficacy when treating GBM in both preclinical and clinical studies, through specific intracellular delivery of cytotoxic anti-microtubule agents such as maytansinoid or monomethyl auristatin F (MMAF) [116]. Here, EGFR is linked to glioblastoma.